Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
Public ClinicalTrials.gov record NCT06234098. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
Study identification
- NCT ID
- NCT06234098
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Alyssum Therapeutics
- Industry
- Enrollment
- 85 participants
Conditions and interventions
Conditions
Interventions
- AT-1965 Liposome Injection Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 12, 2024
- Primary completion
- Nov 30, 2026
- Completion
- Dec 31, 2026
- Last update posted
- May 1, 2025
2024 – 2027
United States locations
- U.S. sites
- 7
- U.S. states
- 4
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CBCC Global Research Site 001 | Scottsdale | Arizona | 85258 | Recruiting |
| CBCC Global Research Site 005 | Bakersfield | California | 93309 | Recruiting |
| CBCC Global Research Site 007 | El Segundo | California | 90245 | Recruiting |
| CBCC Global Research Site 008 | Santa Monica | California | 90403 | Recruiting |
| CBCC Global Research Site 003 | Stanford | California | 94305 | Recruiting |
| CBCC Global Research Site 002 | Portland | Oregon | 97239 | Recruiting |
| CBCC Global Research Site 006 | Dallas | Texas | 75230 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06234098, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06234098 live on ClinicalTrials.gov.